NHS Gender Policy Shift Sparks Fierce Debate
Britain’s gender-care fight just escalated. NHS England has opened a consultation on new rules that would stop routine prescribing of cross-sex hormones for under-18s through its Children and Young People’s Gender Service. Officials say the move is based on limited evidence around long-term safety and effectiveness.
Under the proposal, new referrals for masculinising or feminising hormones would pause. Young people already receiving treatment could continue, but only under individual clinical review. NHS leaders say the policy reflects a more cautious, evidence-led approach after the Cass Review described the evidence around youth gender care as “remarkably weak.”
Critics argue the shift risks denying care to vulnerable young people and warn it could face legal challenges. Supporters say stronger evidence and safety standards must come first when treatments can have lifelong effects.
The result is a growing political and medical clash. The UK is quickly becoming one of the most watched countries in the global debate over youth gender medicine and the NHS decision could shape how other health systems respond.
#NHS #UKPolitics #Healthcare #GenderDebate #CassReview #Britain #MedicalNews #Policy #Opion
